1. Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study
- Author
-
Kaura, A, Hartley, A, Panoulas, V, Glampson, B, Shah, ASV, Davies, J, Mulla, A, Woods, K, Omigie, J, Shah, AD, Thursz, MR, Elliott, P, Hemmingway, H, Williams, B, Asselbergs, FW, O'Sullivan, M, Lord, GM, Trickey, A, Sterne, JA, Haskard, DO, Melikian, N, Francis, DP, Koenig, W, Shah, AM, Kharbanda, R, Perera, D, Patel, RS, Channon, KM, Mayet, J, Khamis, R, Kaura, Amit [0000-0002-6962-3199], Hartley, Adam [0000-0003-1431-2200], Panoulas, Vasileios [0000-0002-9894-9200], Glampson, Ben [0000-0002-5601-5581], Shah, Anoop SV [0000-0002-2825-3419], Davies, Jim [0000-0003-4664-6862], Mulla, Abdulrahim [0000-0002-5943-2348], Woods, Kerrie [0000-0001-8106-8290], Shah, Anoop D [0000-0002-8907-5724], Elliott, Paul [0000-0002-7511-5684], Hemmingway, Harry [0000-0003-2279-0624], Williams, Bryan [0000-0002-8094-1841], Asselbergs, Folkert W [0000-0002-1692-8669], Trickey, Adam [0000-0003-3462-2898], Francis, Darrel P [0000-0002-3410-0814], Koenig, Wolfgang [0000-0002-2064-9603], Shah, Ajay M [0000-0002-6547-0631], Kharbanda, Rajesh [0000-0002-5356-2395], Perera, Divaka [0000-0001-6362-1291], Mayet, Jamil [0000-0002-4665-6422], Khamis, Ramzi [0000-0003-4119-5193], and Apollo - University of Cambridge Repository
- Subjects
Male ,Cohort Studies ,Predictive Value of Tests ,Risk Factors ,General & Internal Medicine ,Humans ,Longitudinal Studies ,Acute Coronary Syndrome ,Mortality ,11 Medical and Health Sciences ,Aged ,Retrospective Studies ,Medicine and health sciences ,Aged, 80 and over ,Biology and life sciences ,United Kingdom/epidemiology ,C-Reactive Protein/metabolism ,General Medicine ,Middle Aged ,Mortality/trends ,United Kingdom ,C-Reactive Protein ,Acute Coronary Syndrome/blood ,Female ,Biomarkers/blood ,Biomarkers ,Research Article ,Follow-Up Studies - Abstract
Funder: THIS Institute, BACKGROUND: There is limited evidence on the use of high-sensitivity C-reactive protein (hsCRP) as a biomarker for selecting patients for advanced cardiovascular (CV) therapies in the modern era. The prognostic value of mildly elevated hsCRP beyond troponin in a large real-world cohort of unselected patients presenting with suspected acute coronary syndrome (ACS) is unknown. We evaluated whether a mildly elevated hsCRP (up to 15 mg/L) was associated with mortality risk, beyond troponin level, in patients with suspected ACS. METHODS AND FINDINGS: We conducted a retrospective cohort study based on the National Institute for Health Research Health Informatics Collaborative data of 257,948 patients with suspected ACS who had a troponin measured at 5 cardiac centres in the United Kingdom between 2010 and 2017. Patients were divided into 4 hsCRP groups (15 mg/L makes it unlikely that sepsis was a major contributor. CONCLUSIONS: These multicentre, real-world data from a large cohort of patients with suspected ACS suggest that mildly elevated hsCRP (up to 15 mg/L) may be a clinically meaningful prognostic marker beyond troponin and point to its potential utility in selecting patients for novel treatments targeting inflammation. TRIAL REGISTRATION: ClinicalTrials.gov - NCT03507309.
- Published
- 2022
- Full Text
- View/download PDF